fbpx

News

Lundbeckfonden Ventures News

Cambridge, UK - 3rd March 2015: Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces that Scott Byrd and Christine Soden have joined its Board of Directors.
Lund, Sweden, (PRNEWSWIRE) February 25, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received regulatory approval from the CDSCO (Central Drugs Standards Control Organization) and their MDAC (Medical Device Approval Committee) to market CERAMENTT'BONE VOID FILLER and...
LEXINGTON, Mass. /PRNewswire/ – scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Pieter Muntendam, President, CEO and founder of scPharmaceuticals, will present at Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Dr. Muntendam will provide an update on the company beginning at 11:30...
SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on January 5, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 13,500 shares...
Vtesse to collaborate with National Institutes of Health on development of VTS-270 for Niemann-Pick Disease Type C and other novel drugs for life-threatening rare diseases
2,000L Demonstration Batch Completed at Lonza, Houston FacilitySAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
SAN DIEGO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.The NASDAQ...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it has filed an action in federal district court for the District of Columbia against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.
Trial using Nexstim's Navigated Brain Therapy (NBT®) system for pain relief in patients suffering from chronicneuropathic painSecond study using Nexstim's technology at The Walton Centre, the only specialist neuroscience centre in the NHS, to show long term effect of NBT®Previous study demonstrated 44% of patients obtained clinically meaningful pain relief of at least 3 weeks'...
1 43 44 45 46 47 65

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. May 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
7. May 2020
Acacia Pharma Group PLC – Alessandro Della Chà appointed as Director of Acacia Pharma Group plc
9. April 2020